Retatrutide is an experimental drug developed by Eli Lilly and Company in the United States for the treatment of obesity. It is a triple glucagon hormone receptor agonist.

In a phase II clinical trial, the drug has been proved to reduce the average weight of non diabetes but obese or pre obese (overweight) adults by more than 17.5%